AbbVie hit with $140 million verdict in AndroGel trial

 

(Reuters) - A U.S. jury on Thursday ordered AbbVie Inc to pay more than $140 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, the plaintiff's lawyer said in a statement.

The verdict, handed down in federal court in Chicago, came in a lawsuit Tennessee resident Jeffrey Konrad and his wife filed in 2015. It is the second verdict against AbbVie to come out of more than 6,000 similar lawsuits against AbbVie and other companies consolidated in the Chicago court.

"We are disappointed with today’s verdict and we intend to appeal," Chicago-based AbbVie said in a statement.

Thursday's verdict was comprised of $140 million in punitive damages, intended to deter the defendant and others from engaging in similar behavior, and $140,000 in compensatory damages, according to David Buchanan, an attorney for Konrad.

Read the full article here.

Add new comment